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SUPPLEMENTAL TEXT 
Supplementary Text: Description of Participating Studies 
Age, Gene/Environment Susceptibility – Reykjavik Study (AGES): The Reykjavik Study cohort 
originally was composed of a random sample of 30,795 men and women born in 1907-1935 and 
living in Reykjavik in 1967.1  A total of 19,381 attended, resulting in 71% recruitment rate. The 
study sample was divided into six groups by birth year and birth date within month. One group 
was designated for longitudinal follow-up and was examined in all stages. Another group was 
designated a control group and was not included in examinations until 1991. Other groups were 
invited to participate in specific stages of the study. Between 2002 and 2006, the AGES-
Reykjavik study re-examined 5,764 survivors of the original cohort who had participated before 
in the Reykjavik Study. 
 
Atherosclerosis Risk in Communities (ARIC) Study: The ARIC study is an ongoing population-
based cohort of 15,792 predominantly Caucasian and African-American males and females aged 
45-64 years at baseline and selected using probability sampling from four United States 
communities (Forsyth County NC, Jackson MS, suburban Minneapolis MN, and Washington 
County MD).2  Participants were recruited in 1987-1989 to examine cardiovascular and 
pulmonary disease, patterns of medical care, and disease variation over time. Standardized 
physical examinations and interviewer-administered questionnaires were conducted at baseline 
(1987-1989), and at three triennial follow-up examinations (1990-1998). Eligible participants for 
this effort were from the NC, MN, and MD field centers, as only Caucasian participants were 
examined in this analysis and the MS center only recruited African American participants.  
 
3 
 
Cardiovascular Health Study (CHS):  The CHS is a population-based cohort study of risk factors 
for CHD and stroke in adults ≥65 years conducted across four field centers.3  The original 
predominantly Caucasian cohort of 5,201 persons was recruited in 1989-1990 from random 
samples of the Medicare eligibility lists; subsequently, an additional predominantly African-
American cohort of 687 persons was enrolled for a total sample of 5,888. DNA was extracted 
from blood samples drawn on all participants at their baseline examination in 1989-90. In 2007-
2008, genotyping was performed at the General Clinical Research Center's 
Phenotyping/Genotyping Laboratory at Cedars-Sinai using the Illumina 370CNV BeadChip 
system on 3,980 CHS participants who were free of CVD at baseline, consented to genetic 
testing, and had DNA available for genotyping. 
 
Erasmus Rucphen Family (ERF) study: The Erasmus Rucphen Family study 
(http://www.erasmusmc.nl/klinische_genetica/research/genepi/?lang=en) is a family-based 
cohort embedded in the Genetic Research in Isolated Populations (GRIP) program in the 
southwest Netherlands.  The aim of this program is to identify genetic risk factors for the 
development of complex disorders. In ERF, twenty-two families that had a minimum of six 
children baptized in the community church between 1850 and 1900 were identified with the help 
of detailed genealogical records. All living descendants of these couples, and their spouses, were 
invited to take part in the study. Comprehensive interviews, questionnaires, and examinations 
were completed at a research center in the area; approximately 3,200 individuals 
participated.  Data collection started in June, 2002 and was completed in February, 2005. In the 
current analyses, 1503 participants for whom complete phenotypic, genotypic and genealogical 
information was available were studied. 
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Framingham Heart Study (FHS): The FHS is a prospective, community based cohort study that 
was initiated in 1948 and now spans 3 generations, including the original cohort, their offspring 
and spouses of the offspring (Offspring Cohort, enrolment- beginning in 1971), and children 
from the largest offspring families (Generation 3 Cohort, enrolment beginning in 2000).  Details 
regarding study recruitment and design have been reported previously.4, 5  Generation 3 cohort 
individuals with ECGs were used for this study.  QT intervals were measured using digital 
calipers on scanned electrocardiograms in leads II (two cardiac cycles), V2 and V5; the average 
across all measurements was taken as the QT trait for analysis.  All study protocols were 
approved by the Institutional Review Board for Boston University Medical Center.  All study 
participants provided informed written consent. 
 
Health, Aging, and Body Composition Study (Health ABC): The Health ABC Study is a NIA-
sponsored cohort study of the factors that contribute to incident disability and the decline in 
function of healthy older persons, with a particular emphasis on changes in body composition in 
old age. Between 4/15/97 and 6/5/98 the Health ABC study has recruited 3,075 70-79 year old 
community-dwelling adults (41% African-American), who were initially free of mobility and 
activities of daily living disability. The key components of Health ABC include a baseline exam, 
annual follow-up clinical exams, and phone contacts every 6 months to identify major health 
events and document functional status between clinic visits.  Provision has been made for 
banking of blood specimens and extracted DNA (Health ABC repository). 
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Health 2000: The Health 2000 Study is a population-based health examination survey carried out 
in Finland in 2000 – 2001.6  A detailed description of the implementation and methodology of 
the survey is available online: http://www.terveys2000.fi/doc/methodologyrep.pdf . The study 
involved a two-stage stratified cluster sample representative of the whole adult Finnish 
population aged > 30 years. The Health 2000 sample comprised 8,028 individuals, of whom 79% 
(6,354 indivduals; 2,876 men and 3,478 women) participated in a comprehensive health 
examination including questionnaires, clinical measurements (e.g. resting ECG) and doctor’s 
physical examination. DNA samples were collected from 6,597 persons and digital EGCs were 
available from 6,295 persons. QT-interval measurements in the Health 2000 Study have been 
described elsewhere.6 
Hispanic Community Health Study / Study of Latinos (SOL): The Hispanic Community Health 
Study (HCHS)/Study of Latinos (SOL) is a community based cohort study of 16,415 self-
identified Hispanic/Latino persons aged 18-74 years from randomly selected households in four 
U.S. field centers (Chicago, IL; Miami, FL; Bronx, NY; San Diego, CA) with baseline 
examination (2008 to 2011) and yearly telephone follow-up assessment for at least three years.7 
The two-stage sampling design selected households within census block groups. Households 
with Hispanic/Latino surnames and individuals over 45 years of age were oversampled to 
achieve increased representation of Hispanic/Latino individuals with a uniform age distribution. 
Due to this study design, sampling weights that reflect the probability of sampling individuals to 
the study were calculated for all individuals.  These sampling weights were used in downstream 
analyses to protect against potential selection bias arising from the sampling scheme. The 
HCHS/SOL cohort includes participants who self-identified as having Hispanic/Latino 
background, the largest groups being Central American, Cuban, Dominican, Mexican, Puerto-
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Rican, and South American. The HCHS/SOL study was approved by institutional review boards 
at participating institutions, and written informed consent was obtained from all participants. 
12,803 individuals were successfully genotyped on an Illumina Omni 2.5M array, and the 
genotype and phenotype data are posted on dbGaP (accession numbers phs000880.v1.p1 and 
phs000810.v1.p1)  
Jackson Heart Study (JHS): The JHS is a single-site, prospective, population-based study 
designed to explore the environmental, behavioral, and genetic factors that influence the 
development of cardiovascular disease (CVD) among African Americans. A total of 5,301 
women and men between the ages of 21 and 94 were recruited between September 2000 and 
May 2004 from a tri-county area of Mississippi: Hinds, Madison, and Rankin Counties. 
Participants were recruited from four sources, including (1) randomly sampled households from 
a commercial listing; (2) ARIC study participants; (3) a structured volunteer sample that was 
designed to mirror the eligible population; and (4) a nested family cohort. Of the enrolled 
participants, 3,630 were recruited uniquely to JHS and did not participate in ARIC. Overviews of 
the JHS including the sampling and recruitment, sociocultural, and laboratory methods have been 
described previously.8 All of the participants provided written informed consent. Participants 
were between 35 and 84 years old at first visit, and members of the family cohort were ≥ 21 
years old when consent for genetic testing was obtained and blood was drawn for DNA 
extraction. The details of first clinic visit procedures, including supine 12-lead digital 
electrocardiography (ECG), venipuncture, and other testing, have been previously described.  
The definitions of co-morbidities as well as the details of ECG measurements and medication 
collection and coding have also been reported.9, 10 
7 
 
Multi-Ethnic Study of Atherosclerosis (MESA): MESA is a study of the characteristics of 
subclinical cardiovascular disease (disease detected non-invasively before it has produced 
clinical signs and symptoms) and the risk factors that predict progression to clinically overt 
cardiovascular disease or progression of the subclinical disease. MESA researchers study a 
diverse, population-based sample of 6,814 asymptomatic men and women aged 45-84. 38 
percent of the recruited participants are white, 28 percent African-American, 22 percent 
Hispanic, and 12 percent Asian, predominantly of Chinese descent.11  Participants were recruited 
from six field centers across the United States. Two physical examinations (at baseline-1st and at 
5th time points) were conducted since the electrocardiography was taken only at baseline and at 
5th time points.   The tenets of the Declaration of Helsinki were followed and institutional review 
board approval was granted at all MESA sites.  Written informed consent was obtained from 
each participant. 
 
The Netherlands Epidemiology of Obesity (NEO) study: The NEO study was designed for 
extensive phenotyping to investigate pathways that lead to obesity-related diseases. The NEO 
study is a population-based, prospective cohort study that includes 6,671 individuals aged 45–65 
years, with an oversampling of individuals with overweight or obesity. At baseline, information 
on demography, lifestyle, and medical history have been collected by questionnaires. In addition, 
samples of 24-h urine, fasting and postprandial blood plasma and serum, and DNA were 
collected. Genotyping was performed using the Illumina HumanCoreExome chip, which was 
subsequently imputed to the 1000 genome reference panel. Participants underwent an extensive 
physical examination, including anthropometry, electrocardiography, spirometry, and 
measurement of the carotid artery intima-media thickness by ultrasonography. In random 
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subsamples of participants, magnetic resonance imaging of abdominal fat, pulse wave velocity of 
the aorta, heart, and brain, magnetic resonance spectroscopy of the liver, indirect calorimetry, 
dual energy X-ray absorptiometry, or accelerometry measurements were performed. The 
collection of data started in September 2008 and completed at the end of September 2012. 
Participants are currently being followed for the incidence of obesity-related diseases and 
mortality.  
 
Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): All data come from the 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). A detailed description of 
the study has been published elsewhere.12, 13  PROSPER was a prospective multicenter 
randomized placebo-controlled trial to assess whether treatment with pravastatin diminishes the 
risk of major vascular events in elderly. Between December 1997 and May 1999, we screened 
and enrolled subjects in Scotland (Glasgow), Ireland (Cork), and the Netherlands (Leiden). Men 
and women aged 70-82 years were recruited if they had pre-existing vascular disease or 
increased risk of such disease because of smoking, hypertension, or diabetes. A total number of 
5,804 subjects were randomly assigned to pravastatin or placebo. A large number of prospective 
tests were performed including Biobank tests and cognitive function measurements.  
 
Rotterdam Study (RS): The RS is a prospective population based cohort study comprising 7,983 
participants aged 55 years or older (RS1), which started in 1990. In 2000-2001, an additional 
3,011 individuals aged 55 years or older were recruited (RS2). Furthermore, in 2006-2008, an 
additional 3,932 individuals aged 45 years or older were recruited (RS3).14  At baseline, 
participants were interviewed at home and were examined at the research center, which included 
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a 10 second, 12-lead electrocardiogram (ECG). Since then, participants are followed 
continuously and re-examined during several follow-up examination rounds. Medical 
information is available of all participants by collaboration with the general practitioners and 
with the pharmacies in the area of Ommoord. The Rotterdam Study has been approved by the 
medical ethics committee according to the “Wet Bevolkingsonderzoek: ERGO” (Population 
Study Act Rotterdam Study), executed by the Ministry of Health, Welfare and Sports of the 
Netherlands and written informed consent was obtained from all study participants. 
 
Women’s Health Initiative Clinical Trials (WHI CT):  The WHI is a long-term national health 
study focused on strategies for preventing heart disease, breast and colorectal cancer, and 
osteoporotic fractures in postmenopausal women.  Between 1993 and 1998, it randomized 
68,132 women aged 50-79 years into one or more clinical trials of hormone therapy, dietary 
modification, or calcium/vitamin D supplementation.15  In this context, white WHI CT women 
were controls drawn from the Genome-wide Association Research Network into Effects of 
Treatment (GARNET),16 controls drawn from the Modification of PM-Mediated 
Arrhythmogenesis in Populations (MOPMAP),17 or participants in the Women's Health Initiative 
Memory Study (WHIMS) .18  Black and Hispanic WHI CT women were participants in the 
single nucleotide polymorphism (SNP) Health Association Resource project (SHARe).19 
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Supplementary Table 1.  Description of Medication Assessment Methods for 14 
Participating Studies Included in the Pharmacogenomic Analysis of QT, QRS, and JT in 
N=78,199 Participants 
Study 
Method of Medication 
Assessment* Time Period 
Number of Visits 
Included in 
Analysis 
AGES Medication Inventory At time of visit 2 
ARIC Medication Inventory 2 weeks before visit ≤4 
CHS Medication Inventory 2 weeks before visit up to 10 
ERF Medication Inventory At time of visit 1 
FHS Medication Inventory At time of visit 1 
Health ABC Medication Inventory 2 weeks before visit 1 
Health 2000 Medication Inventory 1 week before visit 1 
HCHS/SOL Medication Inventory 4 weeks before visit 1 
JHS Medication Inventory At time of visit 1 
MESA Medication Inventory 2 weeks before visit 2 
NEO Medication Inventory At time of visit 1 
PROSPER Medication Inventory At time of visit 1 
RS1 Pharmacy database Prescriptions filled ≤ 30 
days before visit 
5 
RS2 Pharmacy database Prescriptions filled ≤ 30 
days before visit 
3 
RS3 Pharmacy database Prescriptions filled ≤ 30 
days before visit 
1 
WHI GARNET Medication Inventory 2 weeks before visit ≤4 
WHI MOPMAP Medication Inventory 2 weeks before visit ≤4 
WHI WHIMS Medication Inventory 2 weeks before visit ≤4 
WHI CT SHARe Medication Inventory 2 weeks before visit ≤4 
*Medication inventory defined as a structured interview where trained staff member reviewed and recorded all 
medications with participant.   
AGES, Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk in Communities; CHS, 
Cardiovascular Health Study; ERF, Erasmus Rucphen Family Study; FHS, Framingham Heart Study; GARNET, 
Genome-wide Association Research Network into Effects of Treatment; Health ABC, Health, Aging, and Body 
Composition Study;  HCHS/SOL, Hispanic Community Health Study/Study of Latinos; JHS, Jackson Heart Study; 
MESA, Multi-Ethnic Study of Atherosclerosis; MOPMAP, Modification of Particulate Matter-Mediated 
Arrhythmogenesis in Populations; NEO, the Netherlands Epidemiology of Obesity; PROSPER, Prospective Study of 
Pravastatin in the Elderly at Risk; RS, Rotterdam Study; SHARe, The SNP Health Association Resource; WHI CT, 
Women’s Health Initiative Clinical Trial; WHIMS, the WHI Memory Study 
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Supplementary Table 2.  ECG Measurement Methods for 14 Participating Studies Included 
in the Pharmacogenomic Analysis of QT, QRS, and JT in N=78,199 Participants 
Study ECG Machine Measurement System  
AGES Marquette / MAC 5000 Resting ECG  Marquette 12SL 
ARIC Marquette MAC PC Marquette 12SL 
CHS Marquette MAC PC Marquette 12SL 
ERF ACTA electrocardiographs (EASOTE, 
Florence, Italy) 
MEANS20, 21 
FHS GE MAC 5000 Digital calipers 
Health ABC Marquette MAC PC Marquette 12SL 
Health 2000 Marquette MAC 5000 Custom-made software 
HCHS/SOL GE MAC 1200 Marquette 12SL 
JHS Marquette MAC PC MEANS20, 21 
MESA Marquette MAC 1200 Marquette 12SL 
NEO University of Glasgow University of Glasgow 
PROSPER University of Glasgow University of Glasgow 
RS1 ACTA electrocardiographs (EASOTE, 
Florence, Italy) 
MEANS20, 21 
RS2 ACTA electrocardiographs (EASOTE, 
Florence, Italy) 
MEANS20, 21 
RS3 ACTA electrocardiographs (EASOTE, 
Florence, Italy) 
MEANS20, 21 
WHI GARNET Marquette MAC PC Marquette 12SL 
WHI MOPMAP Marquette MAC PC Marquette 12SL 
WHI WHIMS Marquette MAC PC Marquette 12SL 
WHI CT Share Marquette MAC PC Marquette 12SL 
 AGES, Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk in Communities; CHS, 
Cardiovascular Health Study; ERF, Erasmus Rucphen Family Study; FHS, Framingham Heart Study; GARNET, Genome-
wide Association Research Network into Effects of Treatment; Health ABC, Health, Aging, and Body Composition Study;  
HCHS/SOL, Hispanic Community Health Study/Study of Latinos; JHS, Jackson Heart Study; MESA, Multi-Ethnic Study 
of Atherosclerosis; MOPMAP, Modification of Particulate Matter-Mediated Arrhythmogenesis in Populations; NEO, the 
Netherlands Epidemiology of Obesity; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; RS, Rotterdam 
Study; SHARe, The SNP Health Association Resource; WHI CT, Women’s Health Initiative Clinical Trial; WHIMS, the 
WHI Memory Study 
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Supplementary Table 3. Genotyping Characteristics for the 14 Studies Included in the Pharmacogenomics Analysis of QT, QRS, and JT in N=78,199 Participants 
Study Genotyping array 
Genotype 
calling 
algorithm 
Sample 
call rate 
filterb 
SNP call 
rate 
filterb 
SNP 
MAF 
filterb 
HWE 
p-value 
filterb 
Imputation 
software Imputation Platform 
N. autosomal 
SNPs passing 
QC 
AGES Ilumina Hu370CNV BeadStudio >95% >97% <1% 10-6 MACHv.1.16 HapMap2 308,340 
ARIC Affymetrix 6.0 Birdseed <95% <90% <1% <10-5 MACH v1.16 HapMap2 Build 36 669,450 
CHS 
Illumina 370CNV GenomeStudio <95% <97% NA <10-5 
BIMBAM 
0.99 
HapMap2 306,655 
ERF 
Illumina 6K/318K/370K Bead Studio < 98% < 98% < 1% <10-6 
MACH 
v 1.0.15 
HapMap2 487,573 
FHS 
Affymetrix 500K + 50 MIP BRLMM <97% <97% <1% <10-6 
MACH 
v 1.0.15 
HapMap2 378,163 
Health ABC Illumina 1M Beadstudio <97% <97% <1% <10-6 MACH v1.16 HapMap2 914,263 
Health 2000 Illumina Human610-Quad 
BeadChip 
GenCall <95% <95% <1% <10-6 MACH HapMap2 558,388 
HCHS/SOL Illumina Omni 2.5M + 
Custom 
GenomeStudio <98% <98% NA <10-5 IMPUTE2 1000 Genomes Phase 3 2,294,032 
JHS 
Affymetrix 6.0 Birdseed <95% <95% NA NA 
IMPUTE 
v2.1.0 
HapMap P2.r22.b36, 
CEU+YRI 
868,969 
MESA 
Affymetrix 6.0 Birdseed <95% <90% <1% <10-4 
IMPUTE 
v2.1.0 
HapMap2 730,000 
NEO Illumina HumanCoreExome-
24v1_A Beadchip 
GenCall <98% <98% NA <10E-5 IMPUTE2 1000 Genomes 2011 v3 361,046 
PROSPER Illumina 660K Bead studio <90% <97.5% NA <10-6 MACH v1.15 HapMap2 557,192 
RS1 Illumina  550k, 
 
BeadStudio 
 
<98% <98% <1% <10-6 
MACH1 v 
1.0.15, 
HapMap2 512,349 
RS2 Illumina 550K Duo, 
610KQuad 
GenomeStudio <98% <95% <1% <10-6 
MACH 1 v 
1.0.16 
HapMap2 537,405 
RS3 
Illimina 610 Quad Beadstudio <98% <95% <1% <10E-6 
MACH 
v1.0.16 
HapMap2 466,389 
WHI GARNET Illumina Human Omni1-Quad 
v1-0 B 
BeadStudio v3.
1.3.0 
NA ≤98% NA <10E-4 
BEAGLE 
v3.3.1 
1000G v3 3/2012 NA 
WHI MOPMAP Affymetrix Axiom Genome-
Wide Human CEU I 
Birdseed NA ≤90% <0.5% <10E-6 
MaCH 
minimac 
Hapmap 2 
Build 36 
NA 
WHI WHIMS Human OmniExpress Exome-
8v1_B Genome-Wide Human 
Birdseed NA ≤98% <1% <10E-4 
MaCH 
minimac 
Hapmap 2 
Build 36 
NA 
WHI CT SHARe Affymetrix 
GeneChip 
SNP Array 6.0 
Birdseed NA ≤95% <1% <10-6 
MaCH 
v1.0.16 
Hapmap 2 
Build 36 (1:1 CEU:YRI) 
NA 
AGES, Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk in Communities; CHS, Cardiovascular Health Study; ERF, Erasmus Rucphen Family Study; FHS, Framingham 
Heart Study; GARNET, Genome-wide Association Research Network into Effects of Treatment; Health ABC, Health, Aging, and Body Composition Study;  HCHS/SOL, Hispanic Community Health 
Study/Study of Latinos; JHS, Jackson Heart Study; MESA, Multi-Ethnic Study of Atherosclerosis; MOPMAP, Modification of Particulate Matter-Mediated Arrhythmogenesis in Populations; NEO, the 
Netherlands Epidemiology of Obesity; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; RS, Rotterdam Study; SHARe, The SNP Health Association Resource; WHI CT, Women’s Health 
Initiative Clinical Trial; WHIMS, the WHI Memory Study 
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Supplementary Table 4.  Statistical Analysis Methods for 14 Participating Studies Included 
in the Pharmacogenomic Analysis of QT, QRS, and JT in N=78,199 Participants 
Study 
Statistical Analysis (Linear 
Regression, Mixed Model, GEE) 
GWAS Statistical Analysis 
Software  
AGES GEE R bosswithdf 
ARIC GEE R bosswithdf 
CHS GEE R bosswithdf 
ERF Mixed Model GenABEL/ProbABEL 
FHS GEE geepack 
Health ABC GEE R bosswithdf 
Health 2000 Linear Regression ProbABEL v.0.1-6 
HCHS/SOL Mixed Model R 
JHS GEE R bosswithdf 
MESA GEE R bosswithdf 
NEO Linear Regression Probabel v0.4.3 
PROSPER Linear Regression Probabel v0.4.3 
RS1 GEE R bosswithdf 
RS2 GEE R bosswithdf 
RS3 Linear Regression Probabel v0.4.3 
WHI GARNET GEE R bosswithdf 
WHI MOPMAP GEE R bosswithdf 
WHI WHIMS GEE R bosswithdf 
WHI CT Share GEE R bosswithdf 
 AGES, Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk in Communities; CHS, 
Cardiovascular Health Study; ERF, Erasmus Rucphen Family Study; FHS, Framingham Heart Study; GARNET, Genome-
wide Association Research Network into Effects of Treatment; Health ABC, Health, Aging, and Body Composition Study;  
HCHS/SOL, Hispanic Community Health Study/Study of Latinos; JHS, Jackson Heart Study; MESA, Multi-Ethnic Study 
of Atherosclerosis; MOPMAP, Modification of Particulate Matter-Mediated Arrhythmogenesis in Populations; NEO, the 
Netherlands Epidemiology of Obesity; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; RS, Rotterdam 
Study; SHARe, The SNP Health Association Resource; WHI CT, Women’s Health Initiative Clinical Trial; WHIMS, the 
WHI Memory Study 
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Supplementary Table 5.  P-value of Association for Thiazide-SNP Interactive 
Effect on QT Interval in European Descent Populations at 35 Loci Previously 
Associated with QT Interval in Main Effects Genome-Wide Association Studies22 
Index 
SNP* Locus CA 
Main Effect in 
ms (SE)22 
Interaction Effect 
in ms (SE) P 
rs10040989  GFRA3  A -0.85 (0.13) 0.87 (0.44) 0.05 
rs1052536  LIG3  T -0.98 (0.10) -0.56 (0.31) 0.07 
rs10919070  ATP1B1  A 1.68 (0.14) -0.14 (0.44) 0.7 
rs11153730  SLC35F1-PLN  T -1.65 (0.10) -0.15 (0.30) 0.6 
rs11779860  LAPTM4B  T 0.61 (0.10) 0.16 (0.31) 0.6 
rs12143842  NOS1AP  T 3.5 (0.11) 0.29 (0.35) 0.4 
rs1296720  CREBBP  A -0.83 (0.13) 0.57 (0.40) 0.2 
rs12997023  SLC8A1  T 1.69 (0.22) 0.09 (0.72) 0.9 
rs1396515  KCNJ2  C -0.98 (0.09) 0.02 (0.30) 0.9 
rs16936870  NCOA2  A 0.99 (0.16) 1.06 (0.51) 0.04 
rs174583  FEN1-FADS2  T -0.57 (0.09) 0.30 (0.32) 0.3 
rs17784882  C3ORF75  A -0.54 (0.10) -0.18 (0.30) 0.6 
rs1805128  KCNE1  T 7.42 (0.85) -1.16 (1.21) 0.3 
rs1961102  AZIN1  T 0.57 (0.10) -0.41 (0.33) 0.2 
rs2072413  KCNH2  T -1.68 (0.11) 0.26 (0.34) 0.4 
rs2273905  ANKRD9  T 0.61 (0.09) -0.20 (0.34) 0.5 
rs2298632  TCEA3  T 0.7 (0.09) -0.11 (0.31) 0.7 
rs2363719  SLC4A4  A 0.97 (0.16) 0.33 (0.50) 0.5 
rs246185  MKL2  T -0.72 (0.10) -0.96 (0.35) 0.005 
rs246196  CNOT1  T 1.73 (0.11) -0.05 (0.34) 0.9 
rs2485376  GBF1  A -0.56 (0.10) 0.13 (0.32) 0.7 
rs295140  SPATS2L  T 0.57 (0.09) -0.40 (0.30) 0.2 
rs3026445  ATP2A2  T -0.62 (0.09) -0.29 (0.31) 0.4 
rs3105593  USP50-TRPM7  T 0.66 (0.10) 0.25 (0.30) 0.4 
rs3857067  SMARCAD1  A 0.51 (0.08) 0.05 (0.30) 0.9 
rs6793245  SCN5A-SCN10A  A -1.12 (0.10) -0.25 (0.33) 0.4 
rs7122937  KCNQ1  T 1.93 (0.12) -0.38 (0.40) 0.3 
rs728926  KLF12  T 0.57 (0.10) -0.13 (0.33) 0.7 
rs735951  LITAF  A -1.15 (0.10) 0.29 (0.33) 0.4 
rs7561149  TTN-CCDC141  T 0.52 (0.09) 0.10 (0.30) 0.7 
rs7765828  GMPR  C -0.55 (0.09) 0.03 (0.31) 0.9 
rs846111  RNF207  C 1.73 (0.13) 0.27 (0.38) 0.5 
rs938291  SP3  C -0.53 (0.09) 0.26 (0.31) 0.4 
rs9892651  PRKCA  T 0.74 (0.10) -0.04 (0.30) 0.9 
rs9920  CAV1  T -0.79 (0.14) -0.44 (0.51) 0.4 
*Index SNP as identified in a GWAS of QT main effects in European descent populations 
CA, Coded allele; P, P-value; SE, Standard error 
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Supplementary Table 6.  Loci with Suggestive Evidence of Modifying the Thiazide-SNP 
Interaction Effect on QRS Interval 
 
Locus SNP Chr Position* CA CAF 
Interaction 
Effect in ms (SE) P Phet 
European Americans         
L3MBTL2 rs139461 22 39941406 T 0.34 0.8 (0.2)  2x10-6 0.8 
CD200R1 rs9864286 3 114147601 A 0.92 1.4 (0.3)  2x10-6 0.7 
EDG1 rs10874488 1 101640388 A 0.95 2.1 (0.4)  3x10-6 0.6 
HM13 rs6088592 20 29615942 A 0.15 -2.4 (0.5)  4x10-6 0.2 
African American         
DDX1 rs2080798 2 15789836 T 0.76 -1.4 (0.3)  1x10-6 0.1 
FAM84A rs6711956 2 14204168 T 0.53 1.2 (0.2)  2x10-6 0.4 
GAP43 rs7638855 3 116617968 T 0.08 -2.8 (0.6)  2x10-6 0.2 
GUSBP1 rs7706102 5 21438324 C 0.92 3.1 (0.7)  3x10-6 0.3 
SV2B rs886144 15 89518356 T 0.47 -1.1 (0.2)  3x10-6 0.5 
SLC35B3 rs850177 6 8517446 T 0.05 -3.3 (0.7)  3x10-6 0.8 
RFP4AP7 rs4363212 8 50466496 A 0.94 2.5 (0.5)  4x10-6 1.0 
KCNQ3 rs2469514 8 133218116 T 0.83 1.5 (0.3)  4x10-6 0.3 
ZCWPW2 rs6777813 3 28527314 A 0.36 1.1 (0.2)  4x10-6 0.7 
FAM65B rs10946735 6 24980918 A 0.16 -1.5 (0.3)  4x10-6 0.9 
RASD2 rs2009681 22 34306117 A 0.76 1.3 (0.3)  5x10-6 1.0 
Hispanic/Latino         
AK2 rs11591185 1 33274771 A 0.08 3.5 (0.7)  9x10-7 0.04 
PKP2 rs12578228 12 33030528 T 0.10 -3.1 (0.7)  2x10-6 0.4 
TRPC7 rs12658104 5 135939584 A 0.03 5.2 (1.1)  2x10-6 0.4 
GATA3 rs10508356 10 8603852 T 0.42 1.7 (0.4)  3x10-6 0.1 
MYRIP rs4557094 3 39690549 T 0.74 2.0 (0.4)  3x10-6 0.4 
TOX2 rs8120207 20 41928841 T 0.04 -3.7 (0.8)  4x10-6 0.2 
PIGM rs2185214 1 158243375 A 0.88 -2.7 (0.6)  5x10-6 0.5 
PITX2 rs4834601 4 112190427 A 0.39 1.8 (0.4)  5x10-6 0.6 
Trans-Ethnic         
GAP43 rs7638855 3 116617968 T 0.07 -2.7 (0.5)  2x10-7 0.6 
CSMD1 rs17066601 8 3463355 T 0.08 3.0 (0.6)  7x10-7 0.09 
CD200R1 rs16860242 3 114125777 A 0.88 1.0 (0.2)  2x10-6 0.4 
TSGA10 rs720228 2 99070979 A 0.42 0.6 (0.1)  2x10-6 0.5 
ASCL1 rs2176822 12 102115378 T 0.94 -1.3 (0.3)  3x10-6 0.6 
DISC1 rs16856677 1 230389995 T 0.20 -1.2 (0.3)  4x10-6 0.06 
EDN1 rs7767845 6 12536024 T 0.97 2.3 (0.5)  4x10-6 0.5 
*Build 36 Base-Pair Position 
CA, Coded allele, CAF, Coded allele frequency; Chr, Chromosome; P, P-value; Phet, P-value of 
heterogeneity; SE, Standard error; SNP, Single nucleotide polymorphism 
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Supplementary Table 7.  Loci with Suggestive Evidence of Modifying the Thiazide-SNP 
Interaction Effect on JT Interval 
 
Locus SNP Chr Position* CA CAF 
Interaction 
Effect in ms (SE) P Phet 
European Americans         
LCLAT1 rs6733641 2 30444156 T 0.27 -2.0 (0.4)  1x10-6 0.2 
TEDDM1 rs171980 1 180693220 A 0.20 1.9 (0.4)  3x10-6 0.4 
ZNF659 rs6806788 3 21450644 T 0.07 3.0 (0.6)  3x10-6 0.7 
FZD8 rs1219593 10 36587628 T 0.83 -2.0 (0.4)  4x10-6 0.9 
NELL1 rs7106157 11 21035410 A 0.55 1.5 (0.3)  4x10-6 0.2 
African American         
AP4E1 rs7176764 15 49045259 A 0.04 7.3 (1.5)  2x10-6 0.4 
LAMA4 rs6926485 6 112630302 T 0.64 -2.2 (0.5)  3x10-6 0.4 
ASH1L rs11264369 1 153626454 T 0.72 2.5 (0.5)  4x10-6 0.9 
DCC rs7236483 18 49367477 A 0.11 3.5 (0.8)  4x10-6 0.6 
Hispanic/Latino         
GALNT13 rs17553946 2 155055407 A 0.23 2.4 (0.5)  9x10-7 0.6 
NFKBIZ rs1672383 3 103114652 T 0.80 -2.4 (0.5)  3x10-6 0.7 
SH3BGRL2 rs12208969 6 80370016 T 0.73 2.0 (0.4)  4x10-6 0.2 
SMARCA2 rs12339569 9 2117762 T 0.96 -4.7 (1.0)  5x10-6 0.2 
TGFBR2 rs7632716 3 30332431 T 0.83 -2.3 (0.5)  5x10-6 0.6 
Trans-Ethnic         
KCNIP4 rs12648787 4 21225700 C 0.67 -1.3 (0.2)  3x10-7 0.6 
SEL1L rs17116425 14 81712421 A 0.89 -1.9 (0.4)  1x10-6 0.8 
ECEL1 rs2741279 2 233053235 T 0.49 -1.3 (0.3)  1x10-6 0.3 
LCA5 rs1485371 6 80235061 T 0.47 -1.1 (0.2)  1x10-6 0.1 
AP4E1 rs7176764 15 49045259 A 0.04 7.3 (1.5)  2x10-6 0.4 
IMPG1 rs6905415 6 76949519 A 0.09 2.0 (0.4)  3x10-6 0.8 
DPP10 rs9308717 2 116212012 A 0.48 1.1 (0.2)  3x10-6 0.1 
*Build 36 Base-Pair Position 
CA, Coded allele, CAF, Coded allele frequency; Chr, Chromosome; P, P-value; Phet, P-value of heterogeneity; 
SE, Standard error; SNP, Single nucleotide polymorphism 
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Supplementary Table 8.  Results of Gene Enrichment Analysis with MAGMA for the Association with the 
Thiazide-SNP Interaction Effect on QRS Interval Among African Americans (N=11,482)  
Gene Chr Start BP Stop BP N SNPs P FDR 
CNTRL 9 122885395 122981207 69 1x10-6 0.01 
CPN1 10 101790555 101836632 33 2x10-6 0.01 
FAM65B 6 24946066 24990562 55 2x10-6 0.01 
RAB14 9 122978737 123008913 31 5x10-6 0.02 
ISY1 3 130329425 130367719 7 1x10-5 0.03 
NELL1 11 20642712 21555077 1227 3x10-5 0.04 
BP, Build 36 Basepair; Chr, Chromosome; FDR, False Discovery Rate; N SNPs, Number of SNPs from Analysis within Gene 
Interval; P, P-value 
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Supplementary Figures  
 
Supplementary Figure 1.  Study- and race/ethnic-specific quantile-quantile plots of P-values for 
thiazide-SNP interaction estimates in all participating studies for QT interval analyses.  AGES, 
Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk in 
Communities; CHS, Cardiovascular Health Study; ERF, Erasmus Rucphen Family Study; FHS, 
Framingham Heart Study; GARNET, Genome-wide Association Research Network into Effects 
19 
 
of Treatment; H2000, Health 2000; Health ABC, Health, Aging, and Body Composition Study;  
HCHS/SOL, Hispanic Community Health Study/Study of Latinos; JHS, Jackson Heart Study; 
MESA, Multi-Ethnic Study of Atherosclerosis; MOPMAP, Modification of Particulate Matter-
Mediated Arrhythmogenesis in Populations; NEO, the Netherlands Epidemiology of Obesity; 
PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; QT, QT interval; RS, 
Rotterdam Study; SHARe, The SNP Health Association Resource; WHI CT, Women’s Health 
Initiative Clinical Trial; WHIMS, the WHI Memory Study 
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Supplementary Figure 2.  Study- and race/ethnic-specific quantile-quantile plots of P-values for 
thiazide-SNP interaction estimates in all participating studies for QRS interval analyses.  AGES, 
Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk in 
Communities; CHS, Cardiovascular Health Study; ERF, Erasmus Rucphen Family Study; FHS, 
Framingham Heart Study; GARNET, Genome-wide Association Research Network into Effects 
of Treatment; H2000, Health 2000; Health ABC, Health, Aging, and Body Composition Study;  
HCHS/SOL, Hispanic Community Health Study/Study of Latinos; JHS, Jackson Heart Study; 
MESA, Multi-Ethnic Study of Atherosclerosis; MOPMAP, Modification of Particulate Matter-
21 
 
Mediated Arrhythmogenesis in Populations; NEO, the Netherlands Epidemiology of Obesity; 
PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; QRS, QRS interval; RS, 
Rotterdam Study; SHARe, The SNP Health Association Resource; WHI CT, Women’s Health 
Initiative Clinical Trial; WHIMS, the WHI Memory Study 
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Supplementary Figure 3.  Study- and race/ethnic-specific quantile-quantile plots of P-values for 
thiazide-SNP interaction estimates in all participating studies for JT interval analyses.  AGES, 
Age, Gene/Environment Susceptibility – Reykjavik Study; ARIC, Atherosclerosis Risk in 
Communities; CHS, Cardiovascular Health Study; ERF, Erasmus Rucphen Family Study; FHS, 
Framingham Heart Study; GARNET, Genome-wide Association Research Network into Effects 
of Treatment; H2000, Health 2000; Health ABC, Health, Aging, and Body Composition Study;  
HCHS/SOL, Hispanic Community Health Study/Study of Latinos; JHS, Jackson Heart Study; 
23 
 
JT, JT interval; MESA, Multi-Ethnic Study of Atherosclerosis; MOPMAP, Modification of 
Particulate Matter-Mediated Arrhythmogenesis in Populations; NEO, the Netherlands 
Epidemiology of Obesity; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; 
RS, Rotterdam Study; SHARe, The SNP Health Association Resource; WHI CT, Women’s 
Health Initiative Clinical Trial; WHIMS, the WHI Memory Study 
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Supplementary Figure 4.  Quantile-quantile plots of P-values for thiazide-SNP interaction 
estimates for QT interval, QRS interval, and JT interval analyses after inverse-variance weighted 
meta-analysis in METAL. 
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Supplementary Figure 5.  Manhattan plots of Bayes factors for thiazide-SNP interaction 
estimates after Bayesian trans-ethnic meta-analysis in MANTRA across European descent, 
African American, and Hispanic/Latino populations.  On each plot, genome-wide significance 
(BF > 106) and suggestive significance (BF > 104) are denoted with lines. 
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Supplementary Figure 6.  Manhattan plots of P-values for thiazide-SNP interaction estimates 
for QRS and JT interval analyses after fixed effects meta-analysis among European descent 
populations, African American populations, Hispanic/Latino populations, and all populations 
(trans-ethnic).  On each plot, genome-wide significance (P < 5x10-8) and suggestive significance 
(P < 5x10-6) are denoted with dashed lines 
 
 
Supplementary Figure 7.  Quantile-quantile plots of P-values for thiazide-SNP interaction 
estimates after cross-phenotype meta-analysis with aSPU in European descent, African 
American, and Hispanic/Latino populations. 
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